Bafna Pharmaceuticals: 7 Stock Signals Investors Are Watching Right Now

Bafna Pharmaceuticals CMP Rs 291.10. 52W range Rs 94.77 to Rs 291.35. Mcap Rs 689 crore. PE 88.44 vs sector 46.85.

Bafna Pharmaceuticals stock signals are unusually layered right now, with the company trading at Rs 291.10, the stock trades close to its 52 week high of Rs 291.35 and well above its 52 week low of Rs 94.77, reflecting a strong rally over the past year. Bafna Pharmaceuticals is a well tracked name in the a Chennai-based manufacturer of finished pharmaceutical formulations spanning Betalactum and Non Betalactum products space, and no single headline captures where the stock stands today.

This article does not make a buy, hold or sell call on Bafna Pharmaceuticals. It lays out seven signals investors commonly watch, each sourced from the company’s latest exchange disclosures and financial statements, so readers can form their own view of what is currently working for the stock and what still needs to be watched.

Click Here to Get Free Investment Predictions

Bafna Pharmaceuticals Stock at a Glance

Before going through each of the seven Bafna Pharmaceuticals stock signals in detail, the snapshot below sets the starting point on price, valuation and balance sheet strength.

1. Earnings Trend at Bafna Pharmaceuticals

Bafna Pharmaceuticals has delivered a one year share price return of over 100 percent, reflecting improved profitability at the Chennai-based manufacturer of Betalactum and Non Betalactum pharmaceutical formulations.

This is the first of the seven Bafna Pharmaceuticals stock signals worth tracking closely into the next results.

2. FII Holding in Bafna Pharmaceuticals

Bafna Pharmaceuticals’s FII holding stood at 9.30 percent as of a recent quarter. DII holding stood at 0.00 percent over the same period.

This is worth revisiting once the next quarterly shareholding disclosure is filed, to see whether the level and direction of change persists.

3. Promoter Holding in Bafna Pharmaceuticals

Promoter holding in Bafna Pharmaceuticals stood at 75.00 percent as of a recent quarter, one of the shareholding signals worth tracking alongside institutional flows.

This is worth revisiting once the next quarterly shareholding disclosure is filed, to see whether the level and direction of change persists.

4. Debt Position at Bafna Pharmaceuticals

Bafna Pharmaceuticals carries a long term debt to equity ratio of 0.38, a manageable level for a pharmaceutical formulations manufacturer.

This is one of the balance sheet signals worth tracking alongside the earnings trend from Signal 1, since capital raising plans can shift the picture from one quarter to the next.

5. Valuation of Bafna Pharmaceuticals Shares

At a P/E ratio of 88.44 against a sector average of 46.85, Bafna Pharmaceuticals trades at a premium to its sector, with a return on equity of 12.26 percent.

Whether that valuation looks justified depends on the earnings trend from Signal 1 continuing, and it is one of the clearer places where the seven signals can pull in different directions at the same time.

6. Technical Trend on the Bafna Pharmaceuticals Chart

The sixth of these Bafna Pharmaceuticals stock signals is the price chart itself. The stock trades close to its 52 week high of Rs 291.35 and well above its 52 week low of Rs 94.77, reflecting a strong rally over the past year.

Over the past year the stock has moved between Rs 94.77 and Rs 291.35, a range worth watching for a break in either direction as the next signal on where sentiment is heading.

7. Corporate Developments at Bafna Pharmaceuticals

The seventh and final of these Bafna Pharmaceuticals stock signals is corporate activity. Bafna Pharmaceuticals, started in 1981 by Mr Bafna Mahaveer Chand and headquartered in Chennai, manufactures tablets, capsules and liquid formulations of Betalactum and Non Betalactum pharmaceutical products, with promoter holding steady at 75.00 percent.

Check the Univest Screener for live fundamentals

What These Bafna Pharmaceuticals Stock Signals Mean Together

None of these seven signals on its own settles the debate on Bafna Pharmaceuticals. Reading them as a set, rather than picking out any single one, is the more balanced way to approach the stock right now. The earnings trend, shareholding pattern, balance sheet position, valuation, technical setup and corporate developments each add one piece of the picture, and they do not all point the same way at the same time.

Investors weighing Bafna Pharmaceuticals would do well to watch the next quarterly results for a read on where margins and profit are heading, alongside the next shareholding pattern update for any shift in institutional positioning. Reading these Bafna Pharmaceuticals stock signals together, rather than in isolation, remains the more balanced approach. As with any single stock, price movements can be volatile and past trends do not guarantee future performance.

Conclusion

Bafna Pharmaceuticals currently sits at the intersection of several moving parts, from earnings and shareholding to valuation and chart trend, and that is exactly what the seven signals above are meant to surface. This article does not recommend buying, holding or selling Bafna Pharmaceuticals shares, and readers should form their own view based on their own research and risk appetite.

Download the Univest iOS App or Univest Android App to track Bafna Pharmaceuticals live price and more such signal based stock research.

FAQs on Bafna Pharmaceuticals Stock Signals

Why is Bafna Pharmaceuticals share price where it is right now?

Ans. Bafna Pharmaceuticals shares are trading The stock trades close to its 52 week high of Rs 291.35 and well above its 52 week low of Rs 94.77, reflecting a strong shaped by the earnings trend, shareholding shifts and technical setup covered in this article, rather than any single factor.

What is Bafna Pharmaceuticals’s current FII holding?

Ans. FII holding in Bafna Pharmaceuticals stood at 9.30 percent as of a recent quarter.

Is Bafna Pharmaceuticals’s debt position a concern right now?

Ans. Bafna Pharmaceuticals carries a long term debt to equity ratio of 0.38, a manageable level for a pharmaceutical formulations manufacturer.

What is the promoter holding in Bafna Pharmaceuticals?

Ans. Promoter holding in Bafna Pharmaceuticals stood at 75.00 percent as of a recent quarter.

Is Bafna Pharmaceuticals expensive compared to its sector?

Ans. At a P/E ratio of 88.44 against a sector average of 46.85, Bafna Pharmaceuticals trades at a premium to its sector, with a return on equity of 12.26 percent.

What recent corporate developments are relevant to Bafna Pharmaceuticals?

Ans. Bafna Pharmaceuticals, started in 1981 by Mr Bafna Mahaveer Chand and headquartered in Chennai, manufactures tablets, capsules and liquid formulations of Betalactum and Non Betalactum pharmaceutical products, with promoter holding steady at 75.00 percent.

What do the technical charts suggest about Bafna Pharmaceuticals right now?

Ans. The stock trades close to its 52 week high of Rs 291.35 and well above its 52 week low of Rs 94.77, reflecting a strong rally over the past year.

Should investors buy Bafna Pharmaceuticals shares at current levels?

Ans. This article does not offer a buy, hold or sell recommendation. It lays out seven Bafna Pharmaceuticals stock signals, earnings, FII holding, promoter holding, debt, valuation, technicals and corporate developments, so investors can weigh each signal and form their own view based on their goals and risk appetite.